Preclinical characterization and in vivo imaging studies of an engineered recombinant technetium-99m-labeled metallothionein-containing anti-carcinoembryonic antigen single-chain antibody

Journal of Nuclear Medicine

Volumn 39, Issue 1, 1998, Pages 47-56

  Pietersz, Geoffrey A ^a   Patrick, Mark R ^b   Chester, Kerry A ^b  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

^b NONE

Author keywords

CEA; Imaging; Immunoscintigraphy; Recombinant antibody; Single chain antibody

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; METALLOTHIONEIN; METALLOTHIONEIN SINGLE CHAIN FRAGMENT TC 99M; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG CLEARANCE; EXPRESSION VECTOR; FEMALE; GENE TECHNOLOGY; ISOTOPE LABELING; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; RADIOIMMUNOASSAY; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; GENETIC ENGINEERING; HUMANS; ISOTOPE LABELING; METALLOTHIONEIN; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; RADIOIMMUNODETECTION; RECOMBINANT PROTEINS; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 0031930652     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Larson SM. Clinical radioimmunodetection, 1978-1988: overview and suggestions for standardization of clinical trials. Cancer Res 1990;50(suppl):892s-898s.
2. Goldenberg DM, Goldenberg H, Sharkey RM, et al. Imaging of colorectal carcinoma with radiolabeled antibodies. Semin Nucl Med 1989;19:262-281.
3. 2 fragments of an anticarcinoembryonic antigen monoclonal antibody: a multicenter study. Cancer Res 1989;49:3095-3103.
4. Siccardi AG. Tumor immunoscintography by means of radiolabeled monoclonal antibodies: multicenter studies of the Italian National Research Council-Special Project "Biomedical Engineering." Cancer Res 1990;50(suppl):899s-903s.
5. Hnatowich DJ, Griffin TW, Kosciuczyk C, et al. Pharmacokinetics of an indium-111-labeled monoclonal antibody in cancer patients. J Nucl Med 1985;26:849-858.
6. Zalutsky MR, Garg PK, Narula AS. Labeling monoclonal antibodies with halogen nuclides. Acta Radiol Suppl 1990;374:141-145.
7. Zalutsky RM, Naruda AS. A method for radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodme. Int Appl Radiat Isot 1987;38:1051-1057.
8. Srivastava PC, Buchsbaum DJ, Alfred JF, Brubaker PG, Hanna DE, Spicker JK. A new conjugating agent for radio-iodination of proteins: low in vivo deiodination for a radiolabeled antibody in a tumour model. Biotechniques 1990;8:556-562.
9. Hiltunen JV. The search for new and improved radiolabeling methods for monoclonal antibodies: a review of different methods. Acta Oncol 1993;8:831-839.
10. 99mTc. Cancer Res 1990;50(suppl):909s-921s.
11. 99mTc-labeled anti-carainoembryonic antigen antibodies: an intraindividual comparison. Cancer Res 1995;55(suppl):5786s-5793s.
12. Pinsky CM, Goldenberg DM, Wlodkowski TJ, Sasso NL, Mojsiak JZ, Hansen HJ. Detection of occult metastases of colorectal cancer by use of anti-CEA Fab′ fragments labeled with technetium-99m. J Nucl Med 1991;32:1052-1059.
13. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution. Microvasc Res 1991;41:252-272.
14. Jain RK, Baxter LT. Mechanisims of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumours: significance of elevated interstitial pressure. Cancer Res 1988;48:7022-7032.
15. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding site barrier. J Nucl Med 1990;32: 1191-1198.
16. Yokota T, Milenic DE, Whitlow M, Schlom J, Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-3408.
17. Chester KA, Begent RH, Robson L, et al. A new way to generate clinically useful antibodies. Lancet 1994;343:455-456.
18. Kagi JHR, Kojima Y. Chemistry and biochemistry of metallothionein. Experientia 1987;52:25-61.
19. Gill SC, Von Hippel PH. Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem 1989;182:319-326.
20. Tom BH, Rutzkyk LP, Jakstys MM, Oyasu R, Kaye CI, Kalian BD. Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro 1976;12:180-191.
21. Abraham R, Buxbaum S, Link J, Smith R, Venti C, Darsley M. Screening and kinetic analysis of recombinant anti-CEA antibody fragments. J Immunol Methods 1995;183: 119-125.
22. Tjandra JJ, Pietersz GA, Teh JG, et al. Phase I clinical trial of drug-monoclonal antibody conjugates in patients with advanced colorectal carcinoma: a preliminary report [published erratum appears in Surgery 1990;107:261]. Surgry 1989;106:533-545.
23. Wong DW, Mishkin F, Lee T. A rapid chemical method of labeling human plasma proteins with 99m-pertechnetate at pH 7.4. Int J Appl Radiat Isot 1978;29:251-253.
24. Rhodes BA, Zamora PO, Newell KD, et al. Technetium-99m labeling of murine monoclonal antibody fragments. J Nucl Med 1986;27:685-693.
25. Chiou RK. The impact of tumor size on the efficacy of monoclonal antibody-targeted radiotherapy: studies using a nude mouse model with human renal cell carcinoma xenografts. J Urol 1991;146:232-237.
26. Sahin U, Hartmann F, Senter P, et al. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody. Cancer Res 1990;50:6944-6948.
27. Milenic DE, Esteban JM, Colcher D. Comparison of methods for the generation of immunoreactive fragments of a monoclonal antibody (B72.3) reactive with human carcinomas. J Immunol Methods 1989;120:71-83.
28. Milenic DE, Yokota T, Filpula DR, et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1991;51:6363-6371.
29. Scatchard G. The attraction of proteins for small molecules and ions. Ann NY Acad Sci 1949;51:660-672.
30. Kanellos J, Pietersz GA, McKenzie IFC, Bonnyman J. Baldas J. Coupling of technetium-99m-nitrido group to monoclonal antibody and use of the complexes for the detection of tumors in mice J Natl Cancer Inst 1986;77:431-439.
31. Paik CH, Eckelman WC, Reba RC, et al. Transchelation of Tc-99m from low affinity to high affinity sites of antibody. Nucl Med Biol 1986;13:359-362.
32. Waalkes MP, Harvey MJ, Klaassen CD. Relative in vitro affinity of hepatic metallothionein for metals. Toxicol Lett 1984;20:33-39.
33. George AJT, Jamar F, Tai M-S, et al. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. Proc Natl Acad Sci USA 1995;92:8358-8362.
34. Pietersz GA, Wenjun L, Sutton VR, et al. In vivo and in vivo antitumor activity of a chimeric anti-CD19 antibody. Cancer lmmunol Immunother 1995;41:53-60.
35. Mount PF, Sutton VR, Li W, et al. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice. Cancer Res 1994;54:6160-6166.
36. 32P labeling of a humanized, anti-carcinoembryonic antigen (hMN-14) antibody fragment. Cancer Res 1995;55(suppl):5968s-5972s.
37. Kortt AA, Malby RL, Caldwell JB, et al. Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex. Eur J Biochem 1994;221:151-157.
38. Casey JL, Keep PA, Chester KA, Robson L, Hawkins RE, Begent RH. Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. J Immunol Methods 1995;179:105-116.
39. Sawyer JR, Tucker PW, Blattner FR. Metal-binding chimeric antibodies expressed in Escherichia coli. Proc Natl Acad Sci USA 1992;89:9754-9758.
40. Virzi F, Winnard P Jr, Fogarasi M, et al. Recombinant metallothionein-conjugated streptavidin labeled with Re-188 and Tc-99m. Bioconjugate Chem 1995;6:139-144.
41. Hnatowich DJ, Mardirossian G, Rusckowski M, Fogarasi M, Virzi F, Winnard P Jr, Directly and indirectly technetium-99m-labeled antibodies: a comparison of in vitro and animal in vivo properties. J Nucl Med 1993;34:109-119.
42. 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen. Cancer Res 1990;50(suppl):904s-908s.
43. Kosmas C, Snook D, Gooden CS, et al. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res 1992;52:904-911.
44. Reardan DT, Meares CF, Goodwin DA, et.al. Antibodies against metal chelates. Nature 1985;316:265-268.
45. Rodwell JD, Alvarez VL, Lee C, et.al. Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations. Proc Natl Acad Sci: USA 1986;83:2632-2636.
46. 99mTc. Int J Radiat Appl Instrum B 1991;18:667-676.
47. Mather SJ, Ellison D. Reduction mediated Tc-99m labeling of monoclonal antibodies. J Nucl Med 1990;31:692-697.
48. Zamora PO, Mercer-Smith JA, Marek MJ, Schulte LD, Rhodes BA. Similarity of copper and Tc-99m binding sites in human IgG Nucl Med Biol 1992;19:797-802.
49. John E, Thakur ML, Wilder S, Alarddin MM, Epstein AL. Technetium-99m-labeled monoclonal antibodies: influence of technetium-99m binding sites. J Nucl Med 1994;35:876-881.
50. Lash LH, Jones DP. Distribution of oxidized and reduced forms of glutathione and cysteine in rat plasma. Arch Biochim Biophys 1985;240:583-592.
51. Cooper AJL. Biochemistry of sulfur-containing amino acids. Annu Rev Biochem 1983;52:187-222.
52. Griffith OW, Meister A. Glutathione: interorgan translocation, turnover and metabolism. Proc Natl Acad Sci USA 1979;76:5606-5610.
53. Sanyal S, Bannerjee S. Cysteine, a chelating moiety for synthesis of technetium-99m radiopharmaceuticals: II. Attempt to synthesize renal tubular radiopharmaceuticals. Nucl Med Biol 1990;17:757-762.
54. Hand PH, Kashmiri SV, Schlom J. Potential for recombinant immunoglobulin constructs in the management of carcinoma. Cancer 1994;73:1105-1113.
55. Mastrostamatis SG, Papadopoulos MS, Pirmettis IC, et al. Tridentate ligands containing the SNS donor atom set as a novel backbone for the development of technetium brain-imaging agents. J Med Chem 1994;37:3212-3218.
56. 99mTc: the role of metabolism and kinetics. Cancer Res 1995;55(suppl):5777s-5785s.
57. Burchiel SW, Hadjian RA, Hladik WB, et al. Pharmacokinetic evaluation of technetium-99-metallothionein-conjugated mouse monoclonal antibody B72.3 in rhesus monkeys. J Nucl Med 1989;30:1351-1357.
58. Beaumier PC, Venkatesan P, Vanderheyden JL, et al. Re-186 radioimmunotherapy of small cell lung carcinoma xenografts in nude mice. Cancer Res 1991;57:676-681.
59. Breitz HB, Weiden PL, Vanderheyden JL, et al. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of Phase I trials. J Nucl Med 1992;33:1099-1109.
60. Palmiter RD, Norstedt G, Gelinas RE, et al. Metallothionein-human growth hormone fusion genes stimulate growth of mice. Science 1983;222:809-814.
61. Low MJ, Hammer RE, Goodman RE, et al. Tissue-specific posttransitional processing of pre-somatostatin encoded by a metallothionein-somatostatin fusion gene in transgenic mice. Cell 1985;41:211-219.